Skip to main content
. 2021 Aug 9;71(1):109–116. doi: 10.1016/j.alit.2021.08.002

Table 2.

Demographic and clinical features of the patients with mastocytosis.

Demographic and clinical features of patients (n = 60)
Age (years, mean ± SD) 43.60 ± 9.90
Gender
 Female (n,%) 34 (56.7%)
 Male (n,%) 26 (43.3%)
Smokers (n,%) 38 (63.3%)
Alcohol consumption (n,%) 10 (16.7%)
Education
 Not going to school (n,%) 4 (6.7%)
 Primary school (n,%) 14 (23.3%)
 High school (n,%) 21 (35%)
 University (n,%) 21 (35%)
Working status (n,%)
 Active work (n,%) 7 (11.7%)
 Flexible work (n,%) 23 (38.3%)
 Housewife (n,%) 19 (31.7%)
 Salary without work (n,%) 6 (10%)
 Retired (n,%) 3 (5%)
 Fired (n,%) 2 (2%)
Comorbid diseases
 Diabetes mellitus (n,%) 9 (15%)
 Hypertension (n,%) 13 (21.7%)
 Hyperlipidemia (n,%) 4 (6.7%)
 Hypothyroidism (n,%) 3 (5%)
 Malignancy (n,%) 2 (3.3%)
Type of mastocytosis
 CM (n,%) 5 (8.3%)
 ISM (n,%) 50 (83.3%)
 AdvSM (n,%) 5 (8.3%)
Duration of disease (years, mean ± SD) 6.27 ± 4.91
Serum baseline tryptase level (kU/L), (median, IQR25-75) 25.7 (12.65–38.55)
Regular visit to hospital for follow-up in LP (n,%) 6 (10%)
Regular visit to hospital for follow-up in RTNP (n,%) 34 (56.7%)

AdvSM, Advanced systemic mastocytosis; CM, Cutaneous mastocytosis; FCV-19S, Fear of COVID-19 scale; ISM, Indolent systemic mastocytosis; LP, Lockdown period; RTNP, Return to Normal period; SD, Standart deviation.